
Keywords: disease progression; GRIPHON; landmark analysis; SERAPHIN; survival; 6MWD; 6-min walk distance; CI; confidence interval; ERA; endothelin receptor antagonist; HR; hazard ratio; PAH; pulmonary arterial hypertension; PDE-5i; phosphodiesterase type-5 inhibito